Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 1;24(1):19-25.
doi: 10.5551/jat.RV16004. Epub 2016 Oct 12.

Racial Differences in the Cholesterol-Lowering Effect of Statin

Ryo Naito  1 , Katsumi Miyauchi, Hiroyuki Daida
Affiliations
Review

Racial Differences in the Cholesterol-Lowering Effect of Statin

Ryo Naito et al. J Atheroscler Thromb. .

Abstract

Statin treatment to reduce low-density lipoprotein cholesterol (LDL-C) is associated with the prevention of cardiovascular events in Western patients. Similar results have been reported in studies conducted in Japan. However, the dose of statins and the degree of LDL-C reduction achieved with statins are different between Asian and Western patients. In addition, there are limited data regarding racial differences in response to statins. In this review, racial differences between Asians and Westerners in response to statins are described.

PubMed Disclaimer

Conflict of interest statement

COI H.D. has received speakers' Bureau/Honoraria from MSD, AstraZeneca, Kowa Pharmaceutical, Sanofi-Aventis, GlaxoSmithKline, Shionogi, Daiichi-Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, and Astellas Pharma and research funds from Takeda Pharmaceutical, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Astellas Pharma, Novartis Pharma, MSD, Sanofi-Aventis, Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, Pfizer, Kowa Pharmaceutical, Shionogi, AstraZeneca, Teijin, and Morinaga Milk Industry. K.M. has received speakers' Bureau/Honoraria from MSD, AstraZeneca, Kowa Pharmaceutical, Sanofi-Aventis, Shionogi, Daiichi-Sankyo, Takeda Pharmaceutical, Pfizer, Astellas Pharma, and Novartis Pharma. RN report no conflicts of interest.

References

    1. Endo A, Kuroda M, Tsujita Y: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot, 1976; 29: 1346-1348 - PubMed
    1. Endo A, Kuroda M, Tanzawa K: Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett, 1976; 72: 323-326 - PubMed
    1. Cholesterol Treatment Trialists' (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681 - PMC - PubMed
    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet, 1994; 344: 1383-1389 - PubMed
    1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009 - PubMed

MeSH terms

Substances